Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and intoxicating because that oh-so-familiar routine of meetings, deadlines, incessant messages, and the like has, of course, returned. To cope, yes, we are firing up the coffee kettle in order to brew cups of stimulation. Our choice today is hot buttered rum. Feel free to join us. Meanwhile, here are some tidbits to help you on your way. Hope all goes well today and you conquer the world …

Sanofi (SNY), Eli Lilly (LLY), and Novo Nordisk (NVO) must face claims they gouged diabetes patients through deceptive price lists for their life-saving drugs, Bloomberg News reports. A federal judge in New Jersey allowed a proposed class-action lawsuit filed by 67 people with diabetes against the companies to proceed on consumer-fraud allegations tied to skyrocketing insulin prices, but tossed racketeering claims. The patients contend the drug makers illegally raised insulin prices to provide rebates for pharmacy benefit managers that decide which medicines get on preferred insurance lists.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might observe that the latest addition to Allergan’s broad shows a real desire to avoid members who might generate controversy …. NOT! God bless you, Bob Hugin ….

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy